/ Novo Nordisk
/ Market Analysis
Novo Nordisk (NVO) Shares Fall on Unexpected 2026 Sales Outlook
Novo Nordisk shares tumbled 18% after the company issued unexpectedly weak 2026 guidance, forecasting sales could decline as much as 13%.
February 04, 2026
Why Is Novo Nordisk Stock Popping in Premarket? Wegovy Pill Wins FDA Approval
Novo Nordisk shares rose more than 7% in premarket trading after the FDA approved its oral Wegovy weight-loss pill.
December 23, 2025
Why did Novo Nordisk’s Stock Crash Over 20% in Premarket Trading Today?
Novo Nordisk stock crashed over 20% in premarket trading after the company cut its 2025 forecast for the second time.
July 29, 2025
Novo Nordisk’s Shares Dip Amid Surprise CEO Exit in Challenging Times for the Firm
Novo Nordisk's surprise CEO departure amid mounting competitive pressures and disappointing clinical results has accelerated the stock's 50% decline since mid-2024.
May 16, 2025
The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
July 12, 2024More from The Tokenist / Novo Nordisk
Back to 
